Rational Design of de novo CCL2 Binding Peptides

Area of Science:

• Immunology and Molecular Biology
• Biochemistry and Structural Biology

Background:

• Chronic inflammation underlies autoimmune diseases like rheumatoid arthritis and atherosclerosis.
• Chemokine C-C motif ligand 2 (CCL2), also known as monocyte chemoattractant protein-1 (MCP-1), is a critical mediator in inflammatory disease progression.
• CCL2 binding to the CCR2 receptor initiates monocyte recruitment and macrophage differentiation, amplifying inflammation.

Purpose of the Study:

• To computationally design high-affinity peptide binders targeting CCL2.
• To block CCL2's interaction with its receptor CCR2 and inhibit inflammatory pathways.
• To explore de novo rational design of cytokine binders using computational modeling.

Main Methods:

• Homology modeling and energy calculations were used to design peptide binders.
• Rosetta mutations were employed to enhance binding affinity and block the CCL2 dimerization site.
• Computational design strategies were utilized to create novel CCL2 cytokine binders.

Main Results:

• An 11-amino acid peptide with high binding affinity for CCL2 was successfully designed.
• Computational mutations improved the peptide's binding affinity in silico.
• The designed peptides showed potential for blocking CCL2 dimerization.

Conclusions:

• Computational modeling and rational design can yield effective CCL2 cytokine binders.
• The developed peptides demonstrate promise for therapeutic intervention in inflammatory and autoimmune diseases.
• Further studies on binding kinetics and in vivo efficacy are warranted to validate computational findings.